Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 2
1988 1
1990 3
1991 3
1993 1
1995 1
1996 2
1998 2
1999 1
2002 2
2003 1
2004 2
2007 1
2008 1
2009 2
2010 4
2011 4
2012 3
2013 5
2014 1
2015 2
2016 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
A phase 3 trial of bevacizumab in ovarian cancer.
Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators. Perren TJ, et al. N Engl J Med. 2011 Dec 29;365(26):2484-96. doi: 10.1056/NEJMoa1103799. N Engl J Med. 2011. PMID: 22204725 Free article. Clinical Trial.
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S; ML18147 Study Investigators. Bennouna J, et al. Lancet Oncol. 2013 Jan;14(1):29-37. doi: 10.1016/S1470-2045(12)70477-1. Epub 2012 Nov 16. Lancet Oncol. 2013. PMID: 23168366 Clinical Trial.
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ; ICON7 trial investigators. Oza AM, et al. Lancet Oncol. 2015 Aug;16(8):928-36. doi: 10.1016/S1470-2045(15)00086-8. Epub 2015 Jun 23. Lancet Oncol. 2015. PMID: 26115797 Free PMC article. Clinical Trial.
[Anus cancer].
Keldsen N, Laurberg S. Keldsen N, et al. Ugeskr Laeger. 1996 Jul 8;158(28):4073-6. Ugeskr Laeger. 1996. PMID: 8701522 Review. Danish.
Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.
Boisen MK, Johansen JS, Dehlendorff C, Larsen JS, Østerlind K, Hansen J, Nielsen SE, Pfeiffer P, Tarpgaard LS, Holländer NH, Keldsen N, Hansen TF, Jensen BB, Jensen BV. Boisen MK, et al. Among authors: keldsen n. Ann Oncol. 2013 Oct;24(10):2554-2559. doi: 10.1093/annonc/mdt253. Epub 2013 Jul 17. Ann Oncol. 2013. PMID: 23864097 Free article. Clinical Trial.
Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer.
Bergmann TK, Brasch-Andersen C, Gréen H, Mirza M, Pedersen RS, Nielsen F, Skougaard K, Wihl J, Keldsen N, Damkier P, Friberg LE, Peterson C, Vach W, Karlsson MO, Brosen K. Bergmann TK, et al. Among authors: keldsen n. Pharmacogenomics J. 2011 Apr;11(2):113-20. doi: 10.1038/tpj.2010.19. Epub 2010 Apr 6. Pharmacogenomics J. 2011. PMID: 20368717
[Palliative medicine education].
Pedersen L, Jensen AB, Enig B, Hansen PV, Herrstedt J, Jensen NV, Keldsen N, Palshof T. Pedersen L, et al. Among authors: keldsen n. Ugeskr Laeger. 2002 Jan 21;164(4):500-2. Ugeskr Laeger. 2002. PMID: 11838424 Danish. No abstract available.
40 results